<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) is <z:hpo ids='HP_0011010'>chronic</z:hpo>, relapsing and multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorder</z:e>, whose diagnosis is essentially clinical </plain></SENT>
<SENT sid="1" pm="."><plain>In recent studies, the <z:chebi fb="68" ids="48706">antagonists</z:chebi> of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha have shown good results in the treatment of mucocutaneous manifestations of BD </plain></SENT>
<SENT sid="2" pm="."><plain>The authors describe three cases of BD with serious mucocutaneous involvement treated with infliximab </plain></SENT>
<SENT sid="3" pm="."><plain>CLINICAL CASE 1: A 16-year-old female patient with an 8-year history of severe bipolar aphtosis </plain></SENT>
<SENT sid="4" pm="."><plain>A rapid clinical response to biological therapy was verified, with partial and total remission of <z:mpath ids='MPATH_579'>ulcers</z:mpath> at 2nd and 6th week of treatment, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>CLINICAL CASE 2: A 56-year-old female patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> nodular <z:mp ids='MP_0011164'>panniculitis</z:mp> of lower limbs, <z:hpo ids='HP_0002829'>arthralgias</z:hpo> and orogenital ulceration </plain></SENT>
<SENT sid="6" pm="."><plain>After 6 weeks of treatment with infliximab, a complete clinical remission was observed </plain></SENT>
<SENT sid="7" pm="."><plain>CLINICAL CASE 3: A 50-year-old female with a 15-year history of relapsing oropharyngeal ulceration </plain></SENT>
<SENT sid="8" pm="."><plain>A good clinical response to biologic therapy was observed </plain></SENT>
<SENT sid="9" pm="."><plain>At 22nd week it was interrupted because frequent dental abscesses </plain></SENT>
<SENT sid="10" pm="."><plain>In our experience, infliximab is an effective therapeutic alternative that should be considered in the presence of mucocutaneous manifestations resistant to conventional therapies </plain></SENT>
</text></document>